150 related articles for article (PubMed ID: 35717870)
1. Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.
Sun Y; Zhang Y; Chen X; Yu A; Du W; Huang Y; Wu F; Yu L; Li J; Wen C; Yang H; Shi Q; Geng M; Huang X; Xu S
Eur J Med Chem; 2022 Sep; 239():114528. PubMed ID: 35717870
[TBL] [Abstract][Full Text] [Related]
2. A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells.
Xu C; Meng F; Park KS; Storey AJ; Gong W; Tsai YH; Gibson E; Byrum SD; Li D; Edmondson RD; Mackintosh SG; Vedadi M; Cai L; Tackett AJ; Kaniskan HÜ; Jin J; Wang GG
Cell Chem Biol; 2022 Mar; 29(3):386-397.e9. PubMed ID: 34469831
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
Piao L; Gao Y; Xu X; Su Y; Wang YD; Zhou J; Gao Y; Fang J; Li Q; Chang S; Kong R
Eur J Med Chem; 2024 Mar; 268():116264. PubMed ID: 38412693
[TBL] [Abstract][Full Text] [Related]
4. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract][Full Text] [Related]
5. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.
He C; Li F; Zhang J; Wu J; Shi Y
J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain.
Kim S; Hwang I; Kim SH; Chung HW; Ji MJ; Moon S; Park HM; Kong G; Hur W
Chem Biol Drug Des; 2023 Sep; 102(3):500-513. PubMed ID: 37072259
[TBL] [Abstract][Full Text] [Related]
7. Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase.
Rathert P
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440470
[TBL] [Abstract][Full Text] [Related]
8. Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.
Böttcher J; Dilworth D; Reiser U; Neumüller RA; Schleicher M; Petronczki M; Zeeb M; Mischerikow N; Allali-Hassani A; Szewczyk MM; Li F; Kennedy S; Vedadi M; Barsyte-Lovejoy D; Brown PJ; Huber KVM; Rogers CM; Wells CI; Fedorov O; Rumpel K; Zoephel A; Mayer M; Wunberg T; Böse D; Zahn S; Arnhof H; Berger H; Reiser C; Hörmann A; Krammer T; Corcokovic M; Sharps B; Winkler S; Häring D; Cockcroft XL; Fuchs JE; Müllauer B; Weiss-Puxbaum A; Gerstberger T; Boehmelt G; Vakoc CR; Arrowsmith CH; Pearson M; McConnell DB
Nat Chem Biol; 2019 Aug; 15(8):822-829. PubMed ID: 31285596
[TBL] [Abstract][Full Text] [Related]
9. NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression.
Jeong GY; Park MK; Choi HJ; An HW; Park YU; Choi HJ; Park J; Kim HY; Son T; Lee H; Min KW; Oh YH; Lee JY; Kong G
Cancer Res; 2021 Jan; 81(1):77-90. PubMed ID: 32967925
[TBL] [Abstract][Full Text] [Related]
10. NSD3: Advances in cancer therapeutic potential and inhibitors research.
Xiu S; Chi X; Jia Z; Shi C; Zhang X; Li Q; Gao T; Zhang L; Liu Z
Eur J Med Chem; 2023 Aug; 256():115440. PubMed ID: 37182335
[TBL] [Abstract][Full Text] [Related]
11. Elevated NSD3 histone methylation activity drives squamous cell lung cancer.
Yuan G; Flores NM; Hausmann S; Lofgren SM; Kharchenko V; Angulo-Ibanez M; Sengupta D; Lu X; Czaban I; Azhibek D; Vicent S; Fischle W; Jaremko M; Fang B; Wistuba II; Chua KF; Roth JA; Minna JD; Shao NY; Jaremko Ł; Mazur PK; Gozani O
Nature; 2021 Feb; 590(7846):504-508. PubMed ID: 33536620
[TBL] [Abstract][Full Text] [Related]
12. Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.
Liu Z; Piao L; Zhuang M; Qiu X; Xu X; Zhang D; Liu M; Ren D
Oncol Rep; 2017 Nov; 38(5):2796-2802. PubMed ID: 28901481
[TBL] [Abstract][Full Text] [Related]
13. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
[TBL] [Abstract][Full Text] [Related]
14. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
Yang L; Tu W; Huang L; Miao B; Kaneshige A; Jiang W; Leng L; Wang M; Wen B; Sun D; Wang S
J Med Chem; 2023 Aug; 66(15):10761-10781. PubMed ID: 37523716
[TBL] [Abstract][Full Text] [Related]
15. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
16. NSD3 in Cancer: Unraveling Methyltransferase-Dependent and Isoform-Specific Functions.
Nuñez Y; Vera S; Baeza V; Gonzalez-Pecchi V
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256018
[TBL] [Abstract][Full Text] [Related]
17. Prospect of targeting lysine methyltransferase NSD3 for tumor therapy.
Li D; Tian T; Ko CN; Yang C
Pharmacol Res; 2023 Aug; 194():106839. PubMed ID: 37400043
[TBL] [Abstract][Full Text] [Related]
18. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Han X; Zhao L; Xiang W; Miao B; Qin C; Wang M; Xu T; McEachern D; Lu J; Wang Y; Metwally H; Yang CY; Kirchhoff PD; Wang L; Matvekas A; Takyi-Williams J; Wen B; Sun D; Ator M; Mckean R; Wang S
J Med Chem; 2023 Jul; 66(13):8822-8843. PubMed ID: 37382562
[TBL] [Abstract][Full Text] [Related]
19. Discovery of highly potent and selective CRBN-recruiting EGFR
Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
[TBL] [Abstract][Full Text] [Related]
20. Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1.
Zhou Q; Wu W; Jia K; Qi G; Sun XS; Li P
Eur J Med Chem; 2022 Dec; 244():114830. PubMed ID: 36228414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
